Is eNAMPT/visfatin a potential serum marker of papillary thyroid cancer?

Publication/Presentation Date

1-1-2022

Abstract

Purpose: The role of nicotinamide phosphoribosyltransferase (NAMPT)/visfatin in a more aggressive course of many malignancies has been proven. Previous studies have noticed the importance of visfatin in thyroid neoplastic tissue, but the diagnostic and prognostic value of its serum concentration has not been investigated so far. Our study aimed to consider whether extracellular NAMPT (eNAMPT) could be a potential serum marker in recurrent papillary thyroid cancer (PTC).

Methods: It was a prospective observational study with consecutive enrolment. We recruited 100 patients with PTC after thyroidectomy with postoperative

Results: The visfatin serum concentrations in patients diagnosed with PTC and in healthy subjects were not statistically significantly different (

Conclusion: We have not found visfatin as a potential serum marker of papillary thyroid cancer. Also, eNAMPT has no prognostic value in assessing the risk of disease recurrence or metastasis in PTC management.

Volume

13

First Page

20420188221090005

Last Page

20420188221090005

ISSN

2042-0188

Disciplines

Medicine and Health Sciences

PubMedID

35450096

Department(s)

Department of Medicine

Document Type

Article

Link to Full Text

Share

COinS